• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Aemetis Reports Revenues of $81 Million for the Third Quarter 2024

    11/12/24 8:00:00 AM ET
    $AMTX
    Major Chemicals
    Industrials
    Get the next $AMTX alert in real time by email

    Revenues Increased 19% Over the Third Quarter of 2023

    CUPERTINO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Aemetis, Inc. (NASDAQ:AMTX), a renewable natural gas and renewable fuels company focused on low and negative carbon intensity products that replace fossil fuels, today announced its financial results for the three and nine months ended September 30, 2024.

    Revenues of $81.4 million for the third quarter of 2024 reflect strong execution by all three of the company's operating segments, with the California Ethanol business generating $45.0 million in revenues, the India Biodiesel business generating $32.2 million in revenues, and the Dairy Renewable Natural Gas (RNG) business generating $4.2 million in revenues.

    "Each of the Aemetis segments increased revenue during the third quarter of 2024 compared to the second quarter of 2024, reflecting underlying strength and growth," stated Todd Waltz, Chief Financial Officer of Aemetis. "Additionally, we anticipate substantial revenue growth from our operating dairies and new dairies under construction when we receive LCFS provisional pathway approvals as well as federal Inflation Reduction Act (IRA) 45Z production tax credits for RNG," added Waltz.

    "The approval of 20 years of Low Carbon Fuel Standard mandates last Friday by CARB is a major milestone for renewable fuels that directly increases revenues and earnings from each of our U.S. businesses and projects in ethanol, biogas, SAF/RD and carbon sequestration," said Eric McAfee, Chairman and CEO of Aemetis.  "In addition to solid growth in our U.S. businesses, our India subsidiary generated $112 million of revenues driven by the one-year, cost-plus contract with government-owned oil marketing companies that ended in Q3 2024, and we appointed a Chief Executive Officer for the India business who is leading our work towards an IPO of the subsidiary."

    We invite investors to review the Aemetis Corporate Presentation on the Aemetis home page prior to the earnings call.

    Today, Aemetis will host an earnings review call at 11:00 a.m. Pacific time (PT).

    Live Participant Dial In (Toll Free): +1-888-506-0062 entry code 139838

    Live Participant Dial In (International): +1-973-528-0011 entry code 139838

    Webcast URL:  https://www.webcaster4.com/Webcast/Page/2211/51559

    For details on the call, please visit http://www.aemetis.com/investors/conference-calls/

    Financial Results for the Three Months Ended September 30, 2024

    Revenues during the third quarter of 2024 were $81.4 million compared to $68.7 million for the third quarter of 2023. Our Keyes plant recognized $45.0 million of revenue during the third quarter with the production of 15.5 million gallons of ethanol. Our Dairy Natural Gas segment sold 85,993 MMBtu from nine operating dairy digesters and also sold 935 thousand RINs and 20 thousand metric tons of LCFS credits to report $4.2 million of revenue during the third quarter. Our India Biodiesel business recognized $32.2 million of revenue primarily from sales to the India Oil Marketing Companies.

    Gross profit for the third quarter of 2024 was $3.9 million, compared to a $492 thousand profit during the third quarter of 2023.

    Selling, general and administrative expenses were $7.8 million during the third quarter of 2024 compared to $9.0 million during the same period in 2023, the decrease in spending was driven primarily by professional services associated with the sale of tax credits during the third quarter of 2023.

    Operating loss was $3.9 million for the third quarter of 2024, compared to operating loss of $8.5 million for the same period in 2023.

    Interest expense, excluding accretion of Series A preferred units in the Aemetis Biogas LLC subsidiary, increased to $11.7 million during the third quarter of 2024 compared to $10.2 million during the third quarter of 2023. Additionally, Aemetis Biogas recognized $3.3 million of accretion of Series A preferred units during the third quarter of 2024 compared to $7.7 million during the third quarter of 2023.

    Net loss was $17.9 million for the third quarter of 2024, compared to net income of $30.7 million for the third quarter of 2023.

    Cash at the end of the third quarter of 2024 was $296 thousand compared to $2.7 million at the close of the fourth quarter of 2023. We recorded investments in capital projects related to the reduction of the carbon intensity of Aemetis ethanol and construction of dairy digesters of $4.5 million for the third quarter of 2024.

    Financial Results for the Nine Months Ended September 30, 2024

    Revenues were $220.6 million for the first three quarters of 2024, compared to $116.0 million for the first three quarters of 2023. The increase in revenue in 2024 was due to strong performance from California Ethanol, India Biodiesel, and Dairy Renewable Natural Gas throughout the nine months of 2024 compared to the same period of 2023.

    Gross profit for the first three quarters of 2024 was $1.5 million, compared to a gross profit of $1.2 million during the first three quarters of 2023.

    Selling, general and administrative expenses were $28.4 million during the first three quarters of 2024, compared to $29.6 million during the first three quarters of 2023, including $4.0 million of fixed costs of goods sold charged to selling, general and administrative during the Keyes plant maintenance period during 2023 and the recognition of a loss on asset disposals of $3.6 million during 2024.

    Operating loss was $26.9 million for the first three quarters of 2024, compared to $28.4 million for the first three quarters of 2023.

    Interest expense was $34.0 million during the first three quarters of 2024, excluding accretion and other expenses of Series A preferred units in our Aemetis Biogas LLC subsidiary, compared to interest expense of $28.9 million during the first three quarters of 2023. Additionally, our Aemetis Biogas LLC subsidiary recognized $10.1 million of accretion and other expenses in connection with preference payments on its preferred stock during the first three quarters of 2024 compared to $20.2 million during the first three quarters of 2023.

    Net loss for the first three quarters of 2024 was $71.3 million, compared to a net loss of $21.0 million during the same period of 2023.

    Investments in capital projects of $13.5 million were made during the first three quarters of 2024, including investments in capital projects related to Aemetis Biogas of $10.9 million.

    About Aemetis

    Headquartered in Cupertino, California, Aemetis is a renewable natural gas, renewable fuel and biochemicals company focused on the operation, acquisition, development, and commercialization of innovative technologies that replace petroleum-based products and reduce greenhouse gas emissions. Founded in 2006, Aemetis is operating and actively expanding a California biogas digester network and pipeline system to convert dairy waste gas into Renewable Natural Gas. Aemetis owns and operates a 65 million gallon per year ethanol production facility in California's Central Valley near Modesto that supplies about 80 dairies with animal feed. Aemetis owns and operates a 60 million gallon per year production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India and Europe. Aemetis is developing a sustainable aviation fuel (SAF) and renewable diesel fuel biorefinery in California to utilize renewable hydrogen, hydroelectric power, and renewable oils to produce low carbon intensity renewable jet and diesel fuel. For additional information about Aemetis, please visit www.aemetis.com.

    Non-GAAP Financial Information

    We have provided non-GAAP measures as a supplement to financial results based on GAAP. A reconciliation of the non-GAAP measures to the most directly comparable GAAP measures is included in the accompanying supplemental data. Adjusted EBITDA is defined as net income/(loss) plus (to the extent deducted in calculating such net income) interest expense, income tax expense, intangible and other amortization expense, accretion expense, depreciation expense, loss on asset disposal, gain on debt extinguishment, USDA cash grants and share-based compensation expense.

    Safe Harbor Statement

    This news release contains forward-looking statements, including statements regarding assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements include, without limitation, projections of financial results in 2024 and future years; statements relating to the development, engineering, financing, construction and operation of the Aemetis ethanol, biodiesel, biogas, SAF and renewable diesel, and carbon sequestration facilities; and our ability to promote, develop and deploy technologies to produce renewable fuels and biochemicals. Words or phrases such as "anticipates," "may," "will," "should," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "showing signs," "targets," "view," "will likely result," "will continue" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, and other risks detailed in our reports filed with the Securities and Exchange Commission, including our Annual Reports on Form 10-K, and in our other filings with the SEC. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.

    External Investor Relations

    Contact:

    Kirin Smith

    PCG Advisory Group

    (646) 863-6519

    [email protected]

    Investor Relations/

    Media Contact:

    Todd Waltz

    (408) 213-0940

    [email protected]

    (Tables follow)

    AEMETIS, INC.

    CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

    (unaudited, in thousands, except per share data)

      For the three months ended

    September 30,
      For the nine months ended

    September 30,
     
      2024  2023  2024  2023 
    Revenues $81,441  $68,690  $220,636  $115,953 
    Cost of goods sold  77,563   68,198   219,176   114,800 
    Gross profit  3,878   492   1,460   1,153 
                     
    Selling, general and administrative expenses  7,750   9,021   28,400   29,595 
    Operating loss  (3,872)  (8,529)  (26,940)  (28,442)
                     
    Other expense (income):                
    Interest expense                
    Interest rate expense  10,096   8,749   29,092   24,126 
    Debt related fees and amortization expense  1,651   1,433   4,892   4,732 
    Accretion and other expenses of Series A preferred units  3,267   7,739   10,055   20,188 
    Other income  (1,225)  (1,853)  (1,176)  (2,020)
    Loss before income taxes  (17,661)  (24,597)  (69,803)  (75,468)
    Income tax expense (benefit)  274   (55,308)  1,537   (54,490)
    Net Income (loss) $(17,935) $30,711  $(71,340) $(20,978)
                     
    Net Income (loss) per common share                
    Basic $(0.38) $0.79  $(1.60) $(0.56)
    Diluted $(0.38) $0.73  $(1.60) $(0.56)
                     
    Weighted average shares outstanding                
    Basic  47,216   38,881   44,517   37,504 
    Diluted  47,216   41,841   44,517   37,504 



    AEMETIS, INC.

    CONSOLIDATED CONDENSED BALANCE SHEETS

    (in thousands)

      September 30, 2024  December 31, 2023 
      (Unaudited)     
    Assets        
    Current assets:        
    Cash and cash equivalents $296  $2,667 
    Accounts receivable  8,027   8,633 
    Inventories  19,792   18,291 
    Prepaid and other current assets  6,785   6,809 
    Total current assets  34,900   36,400 
             
    Property, plant and equipment, net  195,939   195,108 
    Other assets  16,586   11,898 
    Total assets $247,425  $243,406 
             
    Liabilities and stockholders' deficit        
    Current liabilities:        
    Accounts payable $37,254  $32,132 
    Current portion of long term debt  55,797   13,585 
    Short term borrowings  21,418   23,443 
    Other current liabilities  17,773   15,229 
    Total current liabilities  132,242   84,389 
             
    Total long term liabilities  374,092   375,994 
             
    Stockholders' deficit:        
    Common stock  48   41 
    Additional paid-in capital  293,611   264,058 
    Accumulated deficit  (546,745)  (475,405)
    Accumulated other comprehensive loss  (5,823)  (5,671)
    Total stockholders' deficit  (258,909)  (216,977)
    Total liabilities and stockholders' deficit $247,425  $243,406 



    RECONCILIATION OF ADJUSTED EBITDA TO NET INCOME/(LOSS)

    (unaudited, in thousands)

      For the three months ended

    September 30,
      For the nine months ended

    September 30,
     
    EBITDA Calculation 2024  2023  2024  2023 
                     
    Net income (loss) $(17,935) $30,711   (71,340)  (20,978)
    Adjustments                
    Interest and amortization expense  11,747   10,182   33,984   28,858 
    Depreciation expense  2,274   1,747   6,121   5,208 
    Accretion of Series A preferred units  3,267   7,739   10,055   20,188 
    Loss on asset disposal  -   -   3,644   - 
    Gain on debt extinguishment  (162)  -   (162)  - 
    Share-based compensation  1,982   1,806   6,928   6,223 
    Intangibles amortization expense  12   11   36   35 
    USDA cash grants  -   (1,774)  -   (1,774)
    Income tax expense  274   (55,308)  1,537   (54,490)
    Total adjustments  19,394   (35,597)  62,143   4,248 
                     
    Adjusted EBITDA $1,459  $(4,886)  (9,197)  (16,730)



    PRODUCTION AND PRICE PERFORMANCE

    (unaudited)

      Three Months ended

    September 30,
      Nine Months ended

    September 30,
     
      2024  2023  2024  2023 
    Ethanol                
    Gallons sold (in millions)  15.5   13.8   44.4   16.7 
    Average sales price/gallon $2.12  $2.64  $1.97  $2.72 
    Percent of nameplate capacity  113%  100%  108%  91%
    WDG                
    Tons sold (in thousands)  106   98.0   305   122.0 
    Average sales price/ton $84  $96  $90  $98 
    Delivered Cost of Corn                
    Bushels ground (in millions)  5.5   5.0   15.6   6.4 
    Average delivered cost / bushel $6.07  $7.48  $6.25  $7.34 
    Dairy Renewable Natural Gas                
    MMBtu produced (in thousands)  86.6   66.6   236.3   142.0 
    MMBtu stored as inventory (in thousands)  67.6   67.2   67.6   67.2 
    MMBtu sold (in thousands)  86.0   66.6   234.8   142.0 
    Biodiesel                
    Metric tons sold (in thousands)  26.0   15.5   73.5   42.1 
    Average Sales Price/Metric ton $1,198  $1,247  $1,167  $1,265 
    Percent of Nameplate Capacity  69.3%  41.0%  65.4%  21.0%
    Refined Glycerin                
    Metric tons sold (in thousands)  1.5   1.4   5.4   2.9 
    Average Sales Price/Metric ton $720  $623  $621  $651 


    Primary Logo

    Get the next $AMTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMTX

    DatePrice TargetRatingAnalyst
    8/16/2023$2.50 → $10.50Neutral → Buy
    UBS
    2/28/2023$3.00Underweight
    Piper Sandler
    12/14/2022$4.25Neutral
    UBS
    8/9/2022$12.00Buy → Hold
    Truist
    11/22/2021$31.00 → $35.00Outperform
    Credit Suisse
    8/23/2021$40.00 → $31.00Outperform
    Credit Suisse
    7/15/2021$25.00Outperform
    Evercore ISI Group
    More analyst ratings

    $AMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aemetis upgraded by UBS with a new price target

    UBS upgraded Aemetis from Neutral to Buy and set a new price target of $10.50 from $2.50 previously

    8/16/23 8:55:59 AM ET
    $AMTX
    Major Chemicals
    Industrials

    Piper Sandler initiated coverage on Aemetis with a new price target

    Piper Sandler initiated coverage of Aemetis with a rating of Underweight and set a new price target of $3.00

    2/28/23 6:17:45 AM ET
    $AMTX
    Major Chemicals
    Industrials

    UBS initiated coverage on Aemetis with a new price target

    UBS initiated coverage of Aemetis with a rating of Neutral and set a new price target of $4.25

    12/14/22 7:31:59 AM ET
    $AMTX
    Major Chemicals
    Industrials

    $AMTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aemetis Reports Second Quarter 2025 Financial Results

    Revenue increased $9.3M from the first quarter of 2025 to $52.2M, driven by the restart of India biodiesel deliveries under new order from Oil Marketing Companies.Aemetis Biogas recognized $3.1M in revenue from 11 digesters; CARB approved 7 new LCFS pathways in Q2.Signed $27M agreement with NPL to construct H₂S and compression units for 15 dairy digesters.Operating loss improved by $4.9M from the first quarter of 2025, reflecting reduced SG&A in the second quarter of 2025; net loss flat from the second quarter of 2024 after adjusting for one-time items.Appointed new CFO with IPO experience for our India subsidiary. The India subsidiary is targeting a public listing in early 2026.

    8/7/25 8:00:00 AM ET
    $AMTX
    Major Chemicals
    Industrials

    Aemetis to Review Second Quarter 2025 Financial Results on August 7, 2025

    CUPERTINO, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Aemetis, Inc. (NASDAQ:AMTX) announced that the company will host a conference call to review the release of its second quarter 2025 earnings report: Date: Thursday, August 7, 2025 Time: 11 am Pacific Time (PT) Live Participant Dial In (Toll Free): +1-888-506-0062 entry code 655740 Live Participant Dial In (International): +1-973-528-0011 entry code 655740 Webcast URL: https://www.webcaster4.com/Webcast/Page/2211/52764 Attendees may submit questions during the Q&A (Questions & Answers) portion of the conference call. The webcast will be available on the Company's website (www.aemetis.com) under Investors/Conference Calls, along with

    8/1/25 8:00:00 AM ET
    $AMTX
    Major Chemicals
    Industrials

    Aemetis India Appoints Chief Financial Officer

    CUPERTINO, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Aemetis, Inc. (NASDAQ:AMTX), a renewable natural gas and biofuels company, announced today that its India subsidiary, Universal Biofuels, appointed Anjaneyulu Ganji as Chief Financial Officer, commencing responsibilities on July 17, 2025.  "The growing India economy has increased demand for energy, including biodiesel, ethanol, and compressed natural gas," stated Sanjeev Duggal, Managing Director of Universal Biofuels. "To lead the expansion of Universal, we are very pleased to have a high-quality executive such as Anjan (Anjaneyulu Ganji) join the company as we increase existing production as well as finance and build new biofuels

    7/17/25 8:00:00 AM ET
    $AMTX
    Major Chemicals
    Industrials

    $AMTX
    SEC Filings

    View All

    SEC Form 10-Q filed by Aemetis Inc. (DE)

    10-Q - AEMETIS, INC (0000738214) (Filer)

    8/7/25 10:05:55 AM ET
    $AMTX
    Major Chemicals
    Industrials

    Aemetis Inc. (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AEMETIS, INC (0000738214) (Filer)

    8/7/25 8:45:25 AM ET
    $AMTX
    Major Chemicals
    Industrials

    Aemetis Inc. (DE) filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - AEMETIS, INC (0000738214) (Filer)

    5/16/25 4:22:30 PM ET
    $AMTX
    Major Chemicals
    Industrials

    $AMTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barton Francis P sold $67,016 worth of shares (26,452 units at $2.53), decreasing direct ownership by 11% to 208,518 units (SEC Form 4)

    4 - AEMETIS, INC (0000738214) (Issuer)

    8/14/25 7:49:38 PM ET
    $AMTX
    Major Chemicals
    Industrials

    Director Simon Timothy Alan returned $39,692 worth of shares to the company (20,000 units at $1.98), decreasing direct ownership by 33% to 40,632 units (SEC Form 4)

    4 - AEMETIS, INC (0000738214) (Issuer)

    6/10/25 1:22:43 PM ET
    $AMTX
    Major Chemicals
    Industrials

    EVP, General Counsel Rockett James Michael was granted 27,922 shares (SEC Form 4)

    4 - AEMETIS, INC (0000738214) (Issuer)

    5/19/25 7:44:22 PM ET
    $AMTX
    Major Chemicals
    Industrials

    $AMTX
    Financials

    Live finance-specific insights

    View All

    Aemetis Reports Second Quarter 2025 Financial Results

    Revenue increased $9.3M from the first quarter of 2025 to $52.2M, driven by the restart of India biodiesel deliveries under new order from Oil Marketing Companies.Aemetis Biogas recognized $3.1M in revenue from 11 digesters; CARB approved 7 new LCFS pathways in Q2.Signed $27M agreement with NPL to construct H₂S and compression units for 15 dairy digesters.Operating loss improved by $4.9M from the first quarter of 2025, reflecting reduced SG&A in the second quarter of 2025; net loss flat from the second quarter of 2024 after adjusting for one-time items.Appointed new CFO with IPO experience for our India subsidiary. The India subsidiary is targeting a public listing in early 2026.

    8/7/25 8:00:00 AM ET
    $AMTX
    Major Chemicals
    Industrials

    Aemetis to Review Second Quarter 2025 Financial Results on August 7, 2025

    CUPERTINO, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Aemetis, Inc. (NASDAQ:AMTX) announced that the company will host a conference call to review the release of its second quarter 2025 earnings report: Date: Thursday, August 7, 2025 Time: 11 am Pacific Time (PT) Live Participant Dial In (Toll Free): +1-888-506-0062 entry code 655740 Live Participant Dial In (International): +1-973-528-0011 entry code 655740 Webcast URL: https://www.webcaster4.com/Webcast/Page/2211/52764 Attendees may submit questions during the Q&A (Questions & Answers) portion of the conference call. The webcast will be available on the Company's website (www.aemetis.com) under Investors/Conference Calls, along with

    8/1/25 8:00:00 AM ET
    $AMTX
    Major Chemicals
    Industrials

    Aemetis Reports First Quarter 2025 Financial Results

    California Ethanol passes $2 billion cumulative revenue milestone.Aemetis Biogas increased sales by 10,100 MMBtu compared with same quarter last yearSales of investment tax credits resulted in cash proceeds of $19.0 million during Q1 2025.India Biodiesel received letters of intent in April for an aggregate of $31 million of biodiesel sales to OMCs for delivery in May, June and July of 2025. CUPERTINO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aemetis, Inc. (NASDAQ:AMTX), a renewable natural gas and renewable fuels company focused on low and negative carbon intensity products that replace petroleum products and reduce greenhouse gas emissions, today announced its financial results for the t

    5/8/25 8:00:00 AM ET
    $AMTX
    Major Chemicals
    Industrials

    $AMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Aemetis Inc. (DE) (Amendment)

    SC 13G/A - AEMETIS, INC (0000738214) (Subject)

    2/14/24 4:19:02 PM ET
    $AMTX
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by Aemetis Inc. (DE) (Amendment)

    SC 13G/A - AEMETIS, INC (0000738214) (Subject)

    2/14/24 2:54:17 PM ET
    $AMTX
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by Aemetis Inc. (DE) (Amendment)

    SC 13G/A - AEMETIS, INC (0000738214) (Subject)

    2/13/24 6:50:28 AM ET
    $AMTX
    Major Chemicals
    Industrials

    $AMTX
    Leadership Updates

    Live Leadership Updates

    View All

    Aemetis Appoints J. Michael Rockett as Executive Vice President, General Counsel and Corporate Secretary

    CUPERTINO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aemetis, Inc. (NASDAQ:AMTX), a renewable natural gas and renewable fuels company focused on negative carbon intensity products, has appointed J. Michael Rockett as Executive Vice President, General Counsel and Corporate Secretary, effective immediately. Mr. Rockett brings over 28 years of relevant experience to the company. Prior to joining Aemetis, he was Vice President, General Counsel, and Corporate Secretary of InEnTec Inc., a developer of technology and facilities to convert waste into renewable fuels and chemical products. Mr. Rockett was formerly an attorney at the law firm of Pillsbury Winthrop Shaw Pittman L

    8/28/23 8:00:00 AM ET
    $AMTX
    Major Chemicals
    Industrials

    Aemetis Appoints Former California Public Utilities Commissioner Timothy Simon to the Aemetis Board of Directors

    CUPERTINO, CA, Oct. 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Aemetis, Inc. (NASDAQ:AMTX), a renewable natural gas (RNG) and renewable fuels company focused on negative carbon intensity products, today announced the appointment of Timothy Alan Simon, Esq., former Commissioner of the California Public Utilities Commission (CPUC), to the Company's Board of Directors, effective October 14.  Mr. Simon was appointed to the CPUC by Governor Arnold Schwarzenegger in February 2007, ending his term in December 2012. During his time as a CPUC commissioner, Mr. Simon served as Chair of the National Association of Regulatory Utility Commissioners ("NARUC") Natural Gas Committee; Chair of the

    10/18/21 8:00:00 AM ET
    $AMTX
    Major Chemicals
    Industrials

    Indonesia Energy Corporation Announces Appointment of Michael L. Peterson to Board of Directors

    Experienced energy industry and finance executive to serve as Chairman of IEC's Audit Committee JAKARTA, INDONESIA AND DANVILLE, CA / ACCESSWIRE / January 25, 2021 / Indonesia Energy Corporation (NYSE American:INDO) ("IEC"), an oil and gas exploration and production company focused on Indonesia, today announced that the company's Board of Directors has appointed Michael L. Peterson to the Board. Mr. Peterson will serve as an independent Board member and will also serve as the Chairman of the Audit Committee of the Board of Directors. Mr. Peterson has over 30 years of experience in executive management positions in all aspects of the energy industry and finance industries, having served as

    1/25/21 9:00:00 AM ET
    $PED
    $MEDS
    $INDO
    Oil & Gas Production
    Energy
    Other Pharmaceuticals
    Health Care